You are here

Share:

Search Technologies

Showing 1-20 of 60 results found

A Novel Genetically Encoded Inhibitor of Hippo Signaling Pathway to Study YAP1/TAZ-TEAD Dependent Events in Cancer

The Hippo signaling pathway is one of the most frequently altered pathways in human cancer. Researchers at the National Cancer Institute (NCI) have developed a genetically encoded peptide inhibitor of the Hippo signaling pathway members YAP1/TAZ-TEAD, to dissect and study the specific TEAD-downstream regulatory gene expression networks of cell proliferation, tissue homeostasis, and stem cell functions in different cell types and pathologies. The DNA construct encoding this inhibitor may be delivered to cells using lentivirus, adenovirus, or adeno-associated virus, and is a valuable research tool. NCI seeks licensees for this peptide inhibitor and the encoding DNA construct.

Human Synovial Sarcoma Cell Line A2243

The National Cancer Institute (NCI) seeks parties interested in licensing a human synovial sarcoma cell line (A2243). This cell line is an excellent research tool to study synovial sarcoma with a focus on chromosome translocations.

Development and Characterization of the SLC46A3 Knockout Mouse Line

The National Cancer Institute (NCI) seeks licensees for an SLC46A3 knockout mouse line. SLC46A3 is a solute carrier of the Major Facilitator Superfamily (MFS) and is thought to have roles in multiple diseases including nonalcoholic fatty liver disease, liver cancer and obesity.

AT-3 Mouse Breast Tumor Cell Line

The National Cancer Institute (NCI) seeks licensees for the AT-3 mouse breast tumor cell line derived from an autochthonous tumor model.

CytoSig: A Software Platform for Predicting Cytokine Signaling Activities, Target Discovery, and Clinical Decision Support System (CDSS) from Transcriptomic Profiles

Scientists at the National Cancer Institute (NCI) have developed the Cytokine Signaling Analyzer (CytoSig), a software-based platform that provides both a database of target genes modulated by cytokines and a predictive model of cytokine signaling cascades from transcriptomic profiles. NCI seeks collaborators or licensees to advance the development of CytoSig for research, target discovery, or as a Clinical Decision Support System (CDSS).

SMAD3 Reporter Mouse for Assessing TGF-ß/Activin Pathway Activation

Researchers at the National Cancer Institute (NCI) developed a novel mouse for the detection of TGF-ß signaling. This mouse provides the opportunity to study TGF-ß signaling in vivo and may be a useful model for preclinical pharmacology studies. The NCI seeks licensees for the TGF-ß reporter mouse.

Exo-Clean Technology for Purifying Extracellular Vesicle Preparations from Contaminants

Researchers at the National Cancer Institute (NCI) developed a novel biophysical technique to purify extracellular vesicles (EVs) from contaminants such as proteins and unbound labels. The NCI seeks licensees and/or co-development research collaborations to further advance this technology for EV-based biomarkers and therapeutics to treat a wide range of diseases.

Molecular Nanotags for Detection of Single Molecules

Researchers at the National Cancer Institute (NCI) developed novel molecular nanotags for single biological nanoparticle detection, resolution, and sorting, by flow cytometry. The National Cancer Institute (NCI) seeks licensing and/or co-development research collaborations to further advance this technology with extremely broad biomedical, biodefense, industrial, environmental, and other applications.

Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking

Impairment of cell motility and membrane trafficking can result in enhanced cell proliferation and survival and increased migration and invasion leading to cancer. Several proteins involved in cell motility and membrane trafficking have been shown to be dysregulated in various cancers. Animal models that facilitate the study of roles of these proteins in vivo are therefore required. The National Cancer Institute (NCI) seeks licensees for Mouse Lines with Fluorescently Labelled Membrane Proteins Regulating Cellular Motility and Membrane Trafficking

Improved Antibodies Against ERBB4/HER4

The Eunice Kennedy Shriver National Institute of Child Health and Human Development, Section on Molecular Neurobiology seeks parties interested in licensing or collaborative research to further evaluate or commercialize specific rabbit monoclonal antibodies generated against the ErbB4 receptor (also known as HER4) that have been validated for specificity using tissue sections and extracts from ErbB4 knockout mice.

Methods of Producing Effective T-cell Populations Using Akt Inhibitors

Adoptive cell therapy uses cancer reactive T-cells to effectively treat cancer patients. Producing many persistent T-cells is critical for successful treatments. Researchers at the NCI seek licensing and/or co-development research collaborations for a novel method of producing effective T-cell populations using Akt inhibitors.

Zirconium-89 PET Imaging Agent for Cancer

This technology is a new generation of rationally designed chelating agents that improve the complexation of Zirconium-89 for PET imaging of cancers.

Novel Fixative for Improved Biomolecule Quality from Paraffin-Embedded Tissue

Researchers in the National Cancer Institute’s Laboratory of Pathology have developed an improved tissue fixative solution that is formaldehyde-free. This novel fixative, BE70, significantly improves DNA, RNA, and protein biomolecule integrity in histological samples compared to traditional fixatives. Additionally, BE70 is compatible with current protocols and does not alter tissue processing. NCI seeks partners to license this technology.

BODIPY-FL Nilotinib (Tasigna) for Use in Cancer Research

The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.

Pages